LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Suletud

SektorTervishoid

6.82 0.15

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.74

Max

6.83

Põhinäitajad
By Trading Economics
Sissetulek	3M 8.8M
Müük	2M 54M
P/E Sektori keskmine	9.297 121.746
Kasumimarginaal	16.235
Töötajad	172
EBITDA	2.7M 13M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	93M 347M
Eelmine avamishind	6.67
Eelmine sulgemishind	6.82

Uudiste sentiment

By Acuity

50%

144 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

3.07 / 3.075 Toetus ja vastupanu

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. veebr 2026, 16:32 UTC

Tulu

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14. veebr 2026, 22:02 UTC

Tulu

Looking for Dividends? Consider Europe. -- Barrons.com

14. veebr 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. veebr 2026, 21:57 UTC

Tulu

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. veebr 2026, 21:20 UTC

Tulu

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. veebr 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. veebr 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. veebr 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. veebr 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. veebr 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. veebr 2026, 19:51 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. veebr 2026, 19:29 UTC

Tulu

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. veebr 2026, 18:18 UTC

Omandamised, ülevõtmised, äriostud

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. veebr 2026, 17:52 UTC

Tulu

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. veebr 2026, 17:16 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. veebr 2026, 17:10 UTC

Omandamised, ülevõtmised, äriostud

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. veebr 2026, 16:59 UTC

Tulu

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. veebr 2026, 16:39 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. veebr 2026, 16:11 UTC

Tulu

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. veebr 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. veebr 2026, 15:54 UTC

Tulu

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. veebr 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. veebr 2026, 15:01 UTC

Tulu

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. veebr 2026, 15:00 UTC

Tulu

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. veebr 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. veebr 2026, 14:44 UTC

Tulu

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. veebr 2026, 14:22 UTC

Market Talk

Tulu

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.07 / 3.075Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

144 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.